-
-
-
-
-
-
-
Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies
-
-
-
-
-
-
-
On National Viagra Day, Women Finally Claim Their Turn:
-
-
-
-
-
-
-
Telehealth Now Available for DARE to PLAY™ Sildenafil Cream: First Evidence-Based Topical Arousal Cream for Women
-
-
-
-
-
-
-
Dare Bioscience (DARE) Misses Q3 EPS by 28c
-
-
-
-
-
-
-
Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research
-
-
-
-
-
-
-
Daré Bioscience reports interim Phase 3 results for hormone-free contraceptive
-
-
-
-
-
-
-
Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update
-
1,219,412 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

